Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly Global External R&D VP Robert Armstrong On Attracting Indian Innovators As Partners: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Robert Armstrong, VP, Global External R&D at Eli Lilly is entrusted with perhaps the most challenging task in his organization - cherry-picking the best research partners to help enrich Lilly's pipeline of future drugs - yet keep costs on those multiple research projects as low as possible. Armstrong, who has struck many deals with Indian firms including a joint venture with Jubilant, advocates openness in communication with his partners, but said in an interview with PharmAsia News' India bureau that overcoming challenges and reaching targeted milestones is the true test for strong partnerships.

You may also be interested in...



Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride

Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.

Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride

Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.

India’s Piramal Ropes In Big Pharma Heavyhitters To Support Late-Stage R&D

MUMBAI - A progressively maturing pipeline of innovative compounds has led Piramal Healthcare Ltd. to begin adding leadership positions to its core research team. Piramal is believed to be drawing senior-level executives from established global companies in functions like drug discovery, development, international regulatory affairs and marketing strategies to ramp up expertise in late-stage processes

Related Content

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel